Evaluation of a Competitive Exclusion Culture and Megan Vac 1 on Salmonella Typhimurium Colonization in Neonatal Broiler Chickens

The present study was designed to evaluate the effect of individual or simultaneous application of 2 products, a competitive exclusion culture (CEC) or Megan Vac 1 (MV), for bioefficacy in reducing Salmonella Typhimurium (ST) cecal colonization in broiler chicks following experimental challenge. In experiment 1, CEC and MV were applied to day-of-hatch broiler chicks, and chicks were experimentally challenged with ST approximately 48 h later. In control chicks, ST was recovered at a level of 3.84 log₁₀ cfu/g following direct plating of cecal contents, and 12 of 19 (63.15%) cultured individual ceca were positive following selective enrichment. In chicks receiving CEC by spray application on day of hatch, a numerical reduction in ST recovered from cecal contents (2.63 log₁₀ cfu/g) and a significant reduction (P < 0.05) in recovery of ST from cultured ceca following selective enrichment (4 of 18, or 22.2%) was observed when compared with controls. Significant reductions in ST cecal colonization in chicks treated with MV alone were not observed in experiment 1. In experiment 2, chicks received day-of-hatch spray application of CEC alone, MV alone, or CEC and MV as a combined application immediately prior to or within 24 h of chick placement. When chicks were experimentally challenged with ST 48 h posthatch, significant reductions (P < 0.05) in cecal colonization by ST were observed with each experimental group when compared with nontreated controls. These data suggest that both commercially available products, alone or in combination, are efficacious in reducing cecal colonization in broiler chicks challenged with ST.     

Monitoring the Immune Status of Broilers Against Reoviruses Using Challenge and Serologic Data

Reoviruses are an important cause of suboptimum performance in commercial broilers worldwide. Integrators use the enzyme-linked immunosorbent assay against the S1133 antigen for monitoring serum of breeders for indicating pullet vaccine success. However, without correlating serology to reovirus challenge, it is difficult to determine whether titers reflect protective immunity. We developed a broiler challenge test against 2 common reovirus isolates (2408 and S1133) to evaluate the efficacy of reovirus pullet vaccine programs. Two reovirus serologic and challenge studies were undertaken using chicks from broiler integrators from the southeastern United States. Breeder flocks, from which the chicks were obtained, received at least 1 live and 2 inactivated reovirus vaccines during their pullet phase. One-day-old progeny were collected from 6 breeder flocks. At 1 d of age, 20 chicks from each broiler flock were bled, and serum was analyzed for antibodies. At 3 to 4 d of age, 20 progeny per flock were challenged with the 2408 reovirus by intratracheal route. At 10 to 14 d of age, another 20 birds per flock were challenged with the S1133 reovirus by footpad. Twenty birds per flock were used as nonchallenged controls. At 3 wk of age, all birds were killed and weighed. Percentage of protection was calculated for each flock based on the absence of gross lesions. Flocks with at least 50% protection were considered well protected. Most flocks were well protected against both viruses. The percentage of protection correlated with day-old enzyme-linked immunosorbent assay titers. Chicks from younger hens had higher titers and the best protection against challenge. Producers, whose hen flocks were monitored herein, were doing a good job of immunizing pullets against reovirus. They are now using reovirus progeny challenge studies along with breeder antibody titers to determine vaccination success of their pullets.     

猪瘟病毒及其致病机制研究进展

猪瘟（CSF）是猪的一种高度接触性传染病，该传染病可分为急性、亚急性、慢性、非典型性和不明显型。急性CSF由强毒株引发，一般导致高发病率和死亡率，而弱毒病毒感染则表现不明显。由于疫苗的广泛应用，有效地控制了猪瘟的大流行，减少了急性死亡。但从20世纪80年代以后，临床症状不典型且病程变长的非典型性猪瘟（或慢性猪瘟）成为该病的主要发生形式，持续感染普遍存在，疫苗的预防效果明显下降，使猪瘟防制遇到了新的困难。以目前人类对猪瘟的认识水平，尚难以从分子水平解释这一新变化的成因，这是因为对猪瘟病毒致病机理及其分子基础的认识深度不够。就此，文章综述了猪瘟及猪瘟病毒研究进展，主要涉及CSFV生物学特性、致病机制及其防控，希望能为猪瘟防控提供新的思路和对策。     

免疫佐剂研究进展

佐剂的主要作用是提高抗原（免疫原）的免疫原性和免疫反应的可持续性，它能引导机体的免疫系统对抗原产生体液免疫或细胞免疫反应。对佐剂的选择取决于免疫的目的，从用途上分，佐剂可分为试验用佐剂和疫苗用佐剂。前者主要用于特异性抗体的制备，而后者则作为疫苗的必要成分。文章主要介绍目前常用的几种佐剂包括铝盐佐剂、弗氏佐剂、免疫刺激复合物（ISCOM）、脂质体和CpG及其在科研和疫苗中的应用。     

猪繁殖-呼吸综合征活疫苗对仔猪的安全性试验

本试验用猪繁殖-呼吸综合征（PRRS）活疫苗和国内分离的PRRS强毒CH—1a株接种PRRS阴性的断奶仔猪，分别在接种后的3、7、14d各剖杀1头，取各脏器分别做冰冻切片和病理切片观察。用间接免疫荧光法检测各脏器PRRS病毒的分布。结果表明，PRRS活疫苗在免疫初期，抗原主要分布在脾脏、淋巴结，其次是肾脏和肺脏，少见于肝脏和心脏，第14d时在脾、淋巴结和肾脏有一定量的抗原，而肺脏相比则数量很少，肝脏和心脏未检到PRRS病毒抗原的存在，表明接种PRRS活疫苗随着时间的推移抗原分布呈下降趋势。而强毒抗原分布以脾脏最多，依次是肾脏、肺脏、淋巴结、肝脏、心脏，接种后第14d仍能在各脏器检到PRRS病毒抗原。病理组织学检测结果表明，活疫苗产生以下颌淋巴结、脾脏增生为特征的免疫应答，组织损伤轻微，对肺的病变较少，且仔猪生长良好。强毒则引起以大面积的肺泡隔增宽为特点的间质性肺炎和微循环障碍的病理变化，淋巴小结、脾脏滤泡发生崩解与周围界限不清，个别淋巴细胞核浓缩，组织损伤严重。本试验表明弱毒疫苗对仔猪是安全的。     

中国禽流感诊断技术和疫苗的研究进展

介绍了我国在禽流感诊断技术和疫苗研制方面的一些新技术、新成果，新特点和新思路，分析比较了目前建立的诊断方法和各类疫苗，从整体上展示了我国禽流感诊断技术和疫苗研究状况，对了解和掌握禽流感研究动态，优化禽流感监测手段，调整禽流感防疫策略等有一定的参考价值。     

抗原表位及其在血吸虫疫苗研究中的应用

血吸虫病是世界上危害最严重的寄生虫病之一，其疫苗的研究是世界血吸虫病防治的一项工作重点也是一大难题。抗原表位是疫苗设计和免疫识别的基础，本文对抗原表位在疫苗设计中的分子理论基础做了阐述．介绍了其在血吸虫疫苗设计中的应用，并提出了一些问题与展望。     

猪伪狂犬病病毒双基因缺失突变株(HB-98株)安全性、稳定性和免疫原性测定

对以伪狂犬病病毒鄂A株为亲本毒株构建的TK和gG双基因缺失突变株（PrV HB-98株）的增殖能力、安全性、毒力稳定性和免疫原性进行了测定。结果表明，PrV HB-98株在BHK-21细胞上的增殖滴度为10^7.0 TCID50／0．1mL以上，与亲本毒株相当，但高于Bartha株；与PrV鄂A株相比，病毒量为10^7.0TCID50的PrV HB-98株不引起BALB／c小鼠的死亡，毒力也低于Bartha株；将PrV HB-98株在PK-15细胞连续培养25代和在猪体内上连续继代5次，各代次突变株TK基因和LacZ基因能被稳定扩增，未出现毒力回复现象．表明该毒株具有良好的遗传稳定性；以10^5.0、10^6.0、10^7.0TCID50等3个不同剂量的PrV HB-98株接种于妊娠50～60d母猪和1日龄仔猪，母猪均能正常产仔．仔猪也未出现任何临床症状，证明该毒株有较好的安全性。另外，以10^5.0TCID50的PrV HB-98株接种于妊娠50～60d母猪和1日龄仔猪，分别于接种后28d和20d，用10^7.0TCID50 PrV鄂A强毒进行攻击．结果免疫猪都能抵抗强毒的攻击．获得保护，表明该毒株具有很强的免疫原性。综合上述结果表明，PrV HB-98株可以作为候选毒株．用于伪狂犬病基因工程疫苗的研制。     

H5N2与H5N1禽流感油乳灭活疫苗免疫鹅群对H5N1流行株攻毒的保护效力及母源抗体对免疫效力的干扰

应用H5N2和H5N12种类型禽流感油乳灭活疫苗分别免疫鹅群,观察比较了二者对H5N1型高致病性禽流感病毒的攻毒保护效力。结果表明,在同等剂量免疫条件下,从发病率、死亡率和泄殖腔排毒规律3项指标综合评价来看,H5N1灭活苗水禽免疫组对高致病性禽流感H5N1流行株攻毒的保护效率较H5N2灭活苗理想,且水禽禽流感母源抗体对灭活苗免疫具有一定的干扰作用。     

马链球菌兽疫亚种类M蛋白亚单位疫苗小鼠免疫试验

为获得控制猪链球菌病安全高效的疫苗，本试验进行了马链球菌兽疫亚种类M蛋白亚单位疫苗的研制。应用热酸法提取马链球菌兽疫亚种ATCC35246株类M蛋白，并分别采用羟基磷灰石（HAT）层析和冷酒精沉淀法进行纯化，结果得到较纯的类M蛋白。用热酸提取的粗制类M蛋白、2种纯化的类M蛋白及全菌苗免疫小鼠，结果保护率分别为92％（11／12）、100％（12／12）、100％（12／12）和83％（10／12），表明类M蛋白亚单位疫苗有进一步开发的必要。